Sen. Charles Schumer, D-NY, is in favor of exempting biopharma companies from the Patent and Trademark Office's inter partes review proceedings. However, he said industry may have to be content with modifying the process if legislators are unable to find $1.2bn in pharma-related cost savings.
Speaking at the BIO CEO & Investor Conference in New York Feb. 8, Schumer said he and others in the Senate had proposed that industry be exempted from the patent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?